As Tekmira Puts Cholesterol Rx Trial on Hold, Questions Linger Over Target
September 23, 2010
As Tekmira Puts Cholesterol Rx Trial on Hold, Questions Linger Over Target
The company chalked up the setback to the performance of the lipid nanoparticle used to deliver the drug, but inhibition of the drug's target has been associated with significant side effects.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UniQure, Collaborators Secure $3.2M Eurostar Grant for Huntington’s Disease Effort
May 23, 2013 / Gene Silencing News - NIH Awards $400K to Fund Three microRNA Research Grants in May
May 23, 2013 / Gene Silencing News - Alnylam Releases Proof-of-concept Data on Preclinical Porphyria Drug
May 23, 2013 / Gene Silencing News - MiRagen Hits First Milestone in Servier microRNA Drug Partnership
May 23, 2013 / Gene Silencing News - Cenix to Provide Research Services to Debiopharm
May 23, 2013 / Gene Silencing News